Travere Therapeutics Plans FSGS Submission for Sparsentan
An approval for sparsentan in focal segmental glomerulosclerosis would mark the second rare kidney disease approval for the agent.
Related Articles
Evolocumab May Shift Plaque Profile Toward Lower Cardiovascular Risk
Evolocumab reshapes arterial plaque, reducing cardiovascular risk by lowering microcalcification and shifting plaque composition over 18 months.
New Research Supports GLP-1 RA Use in IBD for Weight Loss, Disease Control
A pair of experts discuss their research on trends in the use of GLP-1 RAs in patients with IBD as well as their safety and…
Unmet Needs in Atopic Dermatitis and the Impact of Roflumilast Cream, with Raj Chovatiya, MD, PhD
In this interview, Raj Chovatiya, MD, PhD, describes roflumilast cream’s success in addressing unmet needs for atopic dermatitis.
How To Go About Proximity Challenges for Food Allergy Anxiety in the Clinic
In a recent review, experts answer frequent questions allergists have about conducting proximity challenges in patients with food allergy anxiety.
New Phase 3 Data on Icotrokinra Suggest Efficacy for Genital, Scalp Psoriasis
These data from the ICONIC-TOTAL trial program highlight icotrokinra’s use as a selective IL-23 inhibitor and its effectiveness in skin clearance for psoriasis.
Evolocumab May Shift Plaque Profile Toward Lower Cardiovascular Risk
Evolocumab reshapes arterial plaque, reducing cardiovascular risk by lowering microcalcification and shifting plaque composition over 18 months.
Anemia
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Retinal Fluid and Visual Acuity After PDS with Ranibizumab, With Veeral Sheth, MD, MBA
A post hoc analysis of trial data reveals the effects of intraretinal fluid on best-corrected visual acuity in patients after port delivery system treatment for…
Shared Decision-Making Needed to Address Environmental, Social Factors of Asthma Management
Explore innovative strategies for asthma management that prioritize shared decision-making and address environmental, social, and behavioral factors.
MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial
MAR001 significantly lowers remnant cholesterol and triglycerides in Phase 2a data, offering hope for high-risk cardiovascular patients.